Poseida Therapeutics To Be Acquired BB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash

Benzinga · Nov 26 14:27

Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash; transaction represents total equity value of up to $1.5 billion

Poseida to join the Roche Group and advance its innovative pipeline of non-viral, TSCM-rich CAR-T therapies and genetic medicines as part of Roche's Pharmaceuticals

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Poseida Therapeutics To Be Acquired BB Roche In $1.5B Deal, Stockholders To Receive Up To $13/ Share In Cash

Risk Disclaimer